echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Study of Nervous System > The p38 alpha inhibitor Neflamapimod was clinically successful in the treatment of Stage II of Louisian dementia, and patients' cognition improved significantly.

    The p38 alpha inhibitor Neflamapimod was clinically successful in the treatment of Stage II of Louisian dementia, and patients' cognition improved significantly.

    • Last Update: 2020-10-21
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    At the 13th Clinical Trials (CTAD) of Alzheimer's Disease, EIP Pharmaceuticals announced that the central nervous system disease drug Neflamapimod (VX745) is treating patients with mild to moderate Louisian dementia (DLB), with Phase II trials reaching the primary endpoint.
    a set of neuropsytherapy tests (NTB) assessments showed significant improvements in cognitive abilities in patients treated with Neflamapimod three times a day.
    addition, several secondary clinical endpoints have also achieved significant statistical improvements.
    in the double-blind placebo-controlled AscenD-LB study, 91 patients were randomly assigned 40 mg of Neflamapimod capsules or placebos at 1:1.
    patients treated with Neflamapimod showed significant cognitive improvement and good tolerance compared to those in the placebo group.
    based on Phase II research, the company plans to advance the development of neflamapimod to Phase III clinical.
    : Neflamapimod is a small molecular drug that penetrates the brain and inhibits in-cell enzyme p38 MAP kinase α (p38 alpha).
    P38 alpha is expressed in neurons under stress and disease conditions and is known to play a major role in inflammation-induced synaptic toxicity, leading to impaired synapse function.
    synapse dysfunction can cause cognitive impairment in a variety of central nervous system diseases, including DLB and Alzheimer's disease.
    Neflamapimod was approved by the U.S. Food and Drug Administration (FDA) as a DLB treatment in November 2019.
    .
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.